schizophrenia; metabolic syndrome; physical health
Abstract :
[en] The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic syndrome in European patients suffering from schizophrenia. Methods: All consecutive patients with schizophrenia at our university psychiatric hospital and affiliate services were entered in an extensive prospective metabolic study including an oral glucose tolerance test. The prevalence of the metabolic syndrome was assessed based on the National Cholesterol Education Program criteria (NCEP, Adult Treatment Protocol, ATP-III), adapted ATP-III criteria using a fasting glucose threshold of 100 mg/dl (AHA) and on the recently proposed criteria from the International Diabetes Federation (IDF). Results: The analysis of 430 patients showed a prevalence of the metabolic syndrome of 28.4% (ATP-III), 32.3% (ATP-III A) and 36% (IDF), respectively. The prevalence of the metabolic syndrome in our sample of patients with schizophrenia is at least twice as high compared to an age-adjusted community sample in Belgium. Conclusion: The metabolic syndrome is highly prevalent among treated patients with schizophrenia. It represents an important risk for cardiovascular and metabolic disorders. Assessment of the presence and monitoring of the associated risks of the metabolic syndrome should be part of the clinical management of patients treated with antipsychotics. (c) 2006 Elsevier B.V. All rights reserved.
Disciplines :
Psychiatry Endocrinology, metabolism & nutrition
Author, co-author :
De Hert, Marc A.
van Winkel, Ruud
Van Eyck, Dominique
Hanssens, Linda
Wampers, Martien
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Peuskens, Joseph
Language :
English
Title :
Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
D.B. Allison, and D.E. Casey Antipsychotic-induced weight gain: a review of the literature J. Clin. Psychiatry 62 Suppl. 7 2001 22 31
D.B. Allison, K.R. Fontaine, M. Heo, J.L. Mentore, J.C. Cappelleri, L.P. Chandler, P.J. Weiden, and L.J. Cheskin The distribution of body mass index among individuals with and without schizophrenia J. Clin. Psychiatry 60 4 1999 215 220
R. Basu, J.S. Brar, K.N. Chengappa, V. John, H. Parepally, S. Gershon, P. Schlicht, and D.J. Kupfer The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype Bipolar Disord. 6 4 2004 314 318
A. Boulogne, and M. Vantyghem Epidemiological data and screening criteria of the metabolic syndrome Presse Med. 5 33(10) 2004 662 665
S. Brown Excess mortality of schizophrenia. A meta-analysis Br. J. Psychiatry 171 1997 502 508
S. Brown, H. Inskip, and B. Barraclough Causes of the excess mortality of schizophrenia Br. J. Psychiatry 177 2000 212 217
T. Cohn, D. Prud'homme, D. Streiner, H. Kameh, and G. Remington Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome Can. J. Psychiatry 49 11 2004 753 760
N. Cossrow, and B. Falkner Race/ethnic issues in obesity and obesity-related comorbidities J. Clin. Endocrinol. Metab. 89 6 2004 2590 2594
De Hert, M., Van Eyck, D., Hanssens, L., Peuskens, H., Thys, E., Wampers, M., Scheen, A., Peuskens, J., in press. Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? Eur Psychiatr (Available online).
A. De Nayer, M. De Hert, A. Scheen, L. Van Gaal, and J. Peuskens Conference report: Belgian consensus on metabolic problems associated with second-generation antipsychotics Int. J. Psychiatry Clin. Pract. 9 2 2005 130 137
L. Dixon, L. Postrado, J. Delahanty, P.J. Fischer, and A. Lehman The association of medical comorbidity in schizophrenia with poor physical and mental health J. Nerv. Ment. Dis. 187 8 1999 496 502
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus Diabetes Care 20 1997 1183 1197
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Follow-up report on the diagnosis of diabetes mellitus Diabetes Care 26 2003 3160 3166
Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
I. Ferreira, J.W. Twisk, W. van Mechelen, H.C. Kemper, and C.D. Stehouwer Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: determinants of the metabolic syndrome in young adults: the Amsterdam growth and health longitudinal study Arch. Intern. Med. 165 1 2005 42 48
E.S. Ford, W.H. Giles, and W.H. Dietz Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey JAMA 287 3 2002 356 359
E.S. Ford, W.H. Giles, and A.H. Mokdad Increasing prevalence of the metabolic syndrome among U.S. adults Diabetes Care 27 10 2004 2444 2449
E.S. Ford, A.H. Mokdad, W.H. Giles, D.A. Galuska, and M.K. Serdula Geographic variation in the prevalence of obesity, diabetes, and obesity-related behaviors Obes. Res. 13 1 2005 118 122
S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer, L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith, and N.J. Stone Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2 2004 227 239
D.W. Haupt, and J.W. Newcomer Hyperglycemia and antipsychotic medications J. Clin. Psychiatry 62 Suppl. 27 2001 15 26 (discussion 40-1)
T. Heiskanen, L. Niskanen, R. Lyytikainen, P.I. Saarinen, and J. Hintikka Metabolic syndrome in patients with schizophrenia J. Clin. Psychiatry 64 5 2003 575 579
P. Homel, D. Casey, and D.B. Allison Changes in body mass index for individuals with and without schizophrenia, 1987-1996 Schizophr. Res. 55 3 2002 277 284
G. Hu, Q. Qiao, J. Tuomilehto, B. Balkau, K. Borch-Johnsen, and K. Pyorala Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women Arch. Intern. Med. 164 10 2004 1066 1076
IDF, 2005. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels, International Diabetes Federation (online).
H. Jin, J.M Meyer, and D.V. Jeste Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases Ann. Clin. Psychiatry 14 1 2002 59 64
H. Jin, J.M. Meyer, and D.V. Jeste Atypical antipsychotics and glucose dysregulation: a systematic review Schizophr. Res. 71 2-3 2004 195 212
A. Kraja, D. Rao, A. Weder, T. Mosley, S. Turner, C. Hsiung, T. Quertermous, R. Cooper, J.D. Curb, and M. Province An evaluation of the metabolic syndrome in a large multi-ethnic study: the Family Blood Pressure Program Nutr. Metab. 2 1 2005 17
C.G. Lyketsos, G. Dunn, M.J. Kaminsky, and W.R. Breakey Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay Psychosomatics 43 1 2002 24 30
S.R. Marder, S.M. Essock, A.L. Miller, R.W. Buchanan, D.E. Casey, J.M. Davis, J.M. Kane, J.A. Lieberman, N.R. Schooler, N. Covell, S. Stroup, E.M. Weissman, D.A. Wirshing, C.S. Hall, L. Pogach, X. Pi-Sunyer, J.T. Bigger, A. Friedman, D. Kleinberg, S.J. Yevich, B. Davis, and S. Shon Physical health monitoring of patients with schizophrenia Am. J. Psychiatry 161 8 2004 1334 1349
J.P. McEvoy, J.M. Meyer, D.C. Goff, H.A. Nasrallah, S.M. Davis, L. Sullivan, H.Y. Meltzer, J. Hsiao, T. Scott Stroup, and J.A. Lieberman Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III Schizophr. Res. 80 1 2005 19 32
L. Meduna, F. Gerty, and V. Urse Biochemical disturbances in mental disorders Arch. Neurol. Psychiatry 47 1942 38 52
J.M. Meyer, and C.E. Koro The effects of antipsychotic therapy on serum lipids: a comprehensive review Schizophr. Res. 70 1 2004 1 17
J.M. Meyer, H.A. Nasrallah, J.P. McEvoy, D.C. Goff, S.M. Davis, M. Chakos, J.K. Patel, R.S.E. Keefe, T. Scott Stroup, and J.A. Lieberman Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III Schizophr. Res. 80 1 2005 9 18
A. Misra, J.S. Wasir, and N.K. Vikram Waist circumference criteria for the diagnosis of abdominal obesity are not applicable uniformly to all populations and ethnic groups Nutrition 21 9 2005 969 976
J.W. Newcomer Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review CNS Drugs 19 Suppl. 1 2005 1 93
U. Osby, N. Correia, L. Brandt, A. Ekbom, and P. Sparen Mortality and causes of death in schizophrenia in Stockholm county, Sweden Schizophr. Res. 45 1-2 2000 21 28
U. Osby, N. Correia, L. Brandt, A. Ekbom, and P. Sparen Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study BMJ 321 7259 2000 483 484
Y.W. Park, S. Zhu, L. Palaniappan, S. Heshka, M.R. Carnethon, and S.B. Heymsfield The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994 Arch. Intern. Med. 163 4 2003 427 436
H. Rakugi, and T. Ogihara The metabolic syndrome in the Asian population Curr. Hypertens. Rep. 7 2 2005 103 109
T.P. Raphael Blood sugar studies in dementia praecox and manic depressive insanity Arch. Neurol. Psychiatry 5 1921 687 709
E. Rietzschel, M. De Buyzere, D. De Bacquer, M. Langlois, S. Bekaert, G. De Backer, and T. Gillebert Metabolic syndrome, a map of the cardiovascular damage. Results from the asklepios study in 2528 apparently healthy 35-55 year old subjects. Abstracts Conference European Society of Cardiology Eur. Heart J. 26 2005 110
D.G. Robinson, M.G. Woerner, J.M. Alvir, R.M. Bilder, G.A. Hinrichsen, and J.A. Lieberman Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder Schizophr. Res. 57 2-3 2002 209 219
A.J. Scheen, and M. De Hert Drug-induced diabetes mellitus: the example of atypical antipsychotics Rev. Med. Liege 60 5-6 2005 455 460
P.J. Weiden, J.A. Mackell, and D.D. McDonnell Obesity as a risk factor for antipsychotic noncompliance Schizophr. Res. 66 1 2004 51 57
